Adalimumab plus topical tacrolimus for the treatment of pyoderma gangrenosum: Report of a case

Marasca, Claudio; Fontanella, Giuseppina; Annunziata, Maria Carmela; Marasca, Dario; Fabbrocini, Gabriella

doi:10.1111/iwj.13123

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ADA, an anti-TNF-α monoclonal antibody, has been approved for the treatment of multiple pediatric conditions [8]. Moreover, the efficacy of off-label therapy with ADA in the treatment of several dermatological disorders, including pyoderma gangrenosum, and IIAF has been reported [9][10][11]. In a previous study, it has been demonstrated that mTOR gene expression was reduced by ADA, suggesting the tight relationship between mTOR pathway and TNF-α [12].…”

Section: Discussionmentioning

confidence: 99%

Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case

Marasca

Fabbrocini

Abategiovanni

et al. 2021

Skin Appendage Disord

Self Cite

View full text Add to dashboard Cite

Acne fulminans (AF) is a rare, acute, and severe form of acne vulgaris often associated with systemic symptoms. Its treatment is challenging and controversial. We report a case of isotretinoin-induced AF (IIAF) in a 12-year-old boy resistant to traditional therapies (oral steroids and isotretinoin). The patient was successfully treated with adalimumab that can be considered an effective off-label option in the treatment of resistant IIAF in children.

show abstract

Section: Discussionmentioning

confidence: 99%

Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case

Marasca

Fabbrocini

Abategiovanni

et al. 2021

Skin Appendage Disord

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immunomodulators such as colchicine, dapsone, minocycline, clofazimine, thalidomide, infliximab, cyclophosphamide, melphalan, chlorambucil, interferon, potassium iodide, and mycophenolate mofetil have also been used for the treatment of PG [ 6 ]. More recently, adalimumab, a tumor necrosis factor-alpha (TNF-α) inhibitor, has also been used to improve patient satisfaction [ 7 , 8 , 9 , 10 ]. However, large ulcers often require months or even years to heal.…”

Section: Introductionmentioning

confidence: 99%

Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs

Nishimura

Mizutani

Yokota

et al. 2022

JCM

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a relatively rare neutrophilic dermatosis presenting as a rapidly progressive and painful skin ulcer characterized by undermined borders and peripheral erythema. Immunosuppressive therapy is the first-line treatment for PG; however, large ulcers often take months or years to heal. Surgical treatments, such as negative pressure wound therapy (NPWT) and skin grafting, are still controversial due to the risk of inducing the pathergy phenomenon and eliciting PG development by traumatic factors. Herein, we report on four cases of PG treated with skin grafting, with or without NPWT, under the control of immunosuppressive drugs at our institution. All cases adapted well, but one case showed recurrence at the periphery of the grafted area five months postoperatively. The current patients were treated with the following doses of oral prednisolone (PSL): PSL 10 mg daily, PSL 5 mg daily + adalimumab 40 mg/week, PSL 12 mg + 6 mg of tacrolimus daily, and PSL 20 mg daily during skin grafting. No severe complications, including infections, were observed. Surgical treatments, such as skin grafting with or without NPWT, may accelerate wound healing, shorten the administration of analgesics and long-term immunosuppressive therapy, and reduce the risk of infection.

show abstract

“…10 Moreover, several cases showed the increased efficacy of the combination of different treatments. 11 Here, we reported the case of a PASH syndrome patient successfully treated with a combination of anti-TNF-α (adalimumab) and a local intensive treatment combined with a multidisciplinary approach. Indeed, we highlighted how this combination treatment could help patients achieve a faster and longterm resolution of the skin lesions.…”

mentioning

confidence: 99%

Wound care, adalimumab, and multidisciplinary approach in a patient affected by PASH syndrome

Zagaria

Ruggiero

Fabbrocini

et al. 2020

International Wound Journal

Self Cite

View full text Add to dashboard Cite

Adalimumab plus topical tacrolimus for the treatment of pyoderma gangrenosum: Report of a case

Cited by 3 publications

References 7 publications

Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case

Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case

Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs

Wound care, adalimumab, and multidisciplinary approach in a patient affected by PASH syndrome

Contact Info

Product

Resources

About